AnticipatedClinical trial: Not allowed
CRI Technology Impact Award
Cancer Research Institute (CRI) · Nonprofit
Source: Cancer Research Institute (CRI) (curated) · View original posting ↗
Annual two-stage cycle (open LOI, then invited full proposal; recent LOI November) — next round not yet posted.
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- Up to $600K
- DeadlineFinal application due date.
- Not yet posted
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- 4 yr
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- —
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Recurring (annual)
- Open dateWhen applications open (or opened).
- —
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $600K total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Not allowed
Early careerEstablished investigatorHigher educationNonprofit
Research areas
Basic mechanisms & biologyTherapeutics & drug discoveryData & infrastructureBiomarkers & diagnosticsClinical trials
Auto-classified from the title and description (keyword-based) — may be imperfect.
Description
Seed awards (up to $600,000 over two to four years) for early-stage technology concepts advancing cancer immunotherapy — computational systems biology, advanced profiling, imaging, and novel therapeutic platforms (excludes clinical trials). Curated entry; verify current terms at the program page.
This funder has no public API, so the entry is manually curated — confirm current amounts, deadlines, and eligibility on the source page.